First patients given novel cell therapy in Leukaemia trial
GammaDelta Therapeutics, a biotechnology company co-founded by researchers from the Francis Crick Institute and King's College London, has announced that it has initiated a First-in-Human Phase I clinical trial in the US, evaluating a unique gamma-delta (γδ) T cell therapy for the treatment of acute myeloid leukaemia.
Published: 15 September 2021